New Study: $10 Generic Drug Lowered LDL Cholesterol by 53%
Research reports significant LDL reductions with an inexpensive drug, raising questions about the push towards higher-cost medications.
Research conducted by TOWARD Health and collaborating institutions has reported LDL cholesterol reductions that nearly triple the conventional response to ezetimibe and fall within the range seen in PCSK9 inhibitor trials.
The study found that a generic drug, costing approximately $10, was able to lower LDL cholesterol by 53 percent. This outcome prompts questions regarding why employers are reportedly being pushed toward medications costing as much as $700 per month.
The findings suggest that this new approach offers an effective and affordable option for managing cardiovascular risk factors. The reported efficacy is comparable to that of PCSK9 inhibitors but at a substantially lower price point.
This research could influence future cholesterol treatment protocols, potentially providing patients and healthcare systems with more cost-effective therapeutic choices.